Exelixis | EXEL - Operating Expenses



Exelixis reported $354.68M in Operating Expenses for its fiscal quarter ending in July of 2025.


Operating Expenses Change Date
Acadia Pharmaceuticals USD 232.19M 7.16M Jun/2025
Agios Pharmaceuticals USD 139.51M 24.16M Jun/2025
Amgen USD 6.52B 337M Jun/2025
AstraZeneca USD 10.95B 1.04B Jun/2025
Bayer EUR 10.73B 688M Jun/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Cytokinetics USD 178.28M 21.06M Jun/2025
Eisai JPY 181.91B 7.35B Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Exelixis USD 354.68M 13.9M Jul/2025
Genmab DKK 565M 38M Jun/2025
Glaxosmithkline GBP 5.55B 1.87B Jun/2025
Incyte USD 904.7M 56.97M Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
MacroGenics USD 59M 23.06M Jun/2025
Merck USD 9.44B 217M Jun/2025
Moderna USD 1.04B 113M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
Novartis USD 9.97B 1.02B Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Sanofi EUR 8.8B 2.03B Jun/2025
Takeda JPY 922.12B 206.21B Jun/2025
Ultragenyx Pharmaceutical USD 274.38M 7.85M Jun/2025
Xencor USD 76.78M 865K Jun/2025